BioXcel Therapeutics (BTAI) News Today → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free BTAI Stock Alerts $2.12 -0.23 (-9.79%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBioXcel Therapeutics Q1 2024 Earnings Previewmsn.com - May 8 at 4:36 PMBioXcel Therapeutics (BTAI) Set to Announce Quarterly Earnings on Thursdayamericanbankingnews.com - May 2 at 4:08 AM2 Contracts Traded for 20JUN24 BTI PHY DN Single Stock Dividend Neutral Futuremsn.com - May 1 at 8:48 AMShort Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Declines By 16.1%marketbeat.com - April 29 at 8:20 PMHold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial Uncertaintiesmarkets.businessinsider.com - April 26 at 8:41 AMBioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024globenewswire.com - April 25 at 7:00 AMBioXcel Therapeutics to launch phase 3 trial for at-home useuk.investing.com - April 24 at 9:35 PMBioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meetingglobenewswire.com - April 24 at 10:30 AMBuy Rating Reaffirmed for BioXcel Therapeutics Amidst Expansion Opportunities and FDA-Approved IGALMI™markets.businessinsider.com - April 23 at 1:45 PMBioXcel Therapeutics (NASDAQ:BTAI) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - April 23 at 8:20 AMBioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potentialglobenewswire.com - April 22 at 7:00 AMQ1 2024 EPS Estimates for BioXcel Therapeutics, Inc. Lifted by HC Wainwright (NASDAQ:BTAI)marketbeat.com - April 18 at 5:59 AMBioXcel Therapeutics stock target cut, retains buy ratinginvesting.com - April 17 at 7:22 PMHC Wainwright Comments on BioXcel Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:BTAI)marketbeat.com - April 17 at 5:55 PMBioXcel Therapeutics (BTAI) Price Target Decreased by 9.82% to 10.71msn.com - April 17 at 2:22 PMBuy Rating Affirmed for Bioxcel Therapeutics Amid Strategic Clinical Trials and Regulatory Potentialmarkets.businessinsider.com - April 15 at 7:24 PMShort Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Drops By 20.7%marketbeat.com - April 13 at 9:15 PMBioXcel Therapeutics to begin phase 3 trial for Alzheimer's treatmentinvesting.com - April 12 at 12:56 AMBioXcel Therapeutics CCO sells $2.6k in stockinvesting.com - April 11 at 12:05 AMBioXcel Therapeutics CSO sells shares worth over $2.8kuk.investing.com - April 10 at 2:03 PMBioxcel Therapeutics exec sells over $400 in stockinvesting.com - April 10 at 2:03 PMBioXcel Therapeutics CEO sells shares worth over $13,000investing.com - April 10 at 2:03 PMBioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementiafinance.yahoo.com - April 10 at 9:03 AMBioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementiaglobenewswire.com - April 10 at 7:00 AMInsider Selling: BioXcel Therapeutics, Inc. (NASDAQ:BTAI) CEO Sells 5,268 Shares of Stockinsidertrades.com - April 9 at 4:48 AMShort Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Decreases By 20.9%marketbeat.com - March 30 at 10:08 AMBioXcel Therapeutics Announces $25 Million Registered Direct Offeringglobenewswire.com - March 25 at 7:00 AMBioXcel Therapeutics Full Year 2023 Earnings: Revenues Disappointfinance.yahoo.com - March 24 at 9:16 AMBioXcel Therapeutics' (BTAI) "Buy" Rating Reaffirmed at HC Wainwrightmarketbeat.com - March 18 at 5:32 PMBioXcel Therapeutics (NASDAQ:BTAI) Price Target Cut to $7.00 by Analysts at Canaccord Genuity Groupmarketbeat.com - March 18 at 4:34 PMBuy Rating Affirmed for BioXcel Therapeutics: FDA Pathway Clear for BXCL501 Expansionmarkets.businessinsider.com - March 18 at 4:27 PMTapeworm eggs found in brain of man with penchant for 'undercooked' baconau.news.yahoo.com - March 15 at 11:18 PMBioXcel Gets European Patent For Sublingual Dexmedetomidine To Treat Agitation In Dementia Patientsmarkets.businessinsider.com - March 15 at 6:17 PMBioxcel Therapeutics: Hold Rating Amid Financial and Operational Uncertaintiesmarkets.businessinsider.com - March 15 at 8:16 AMBioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidinetmcnet.com - March 15 at 8:16 AMBioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidinefinance.yahoo.com - March 15 at 8:16 AMBioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidineglobenewswire.com - March 15 at 7:00 AMPetco CEO Ron Coughlin steps down, ex-BestBuy exec named as replacementmsn.com - March 15 at 1:30 AMFDA approves first drug for serious liver diseasemsn.com - March 15 at 1:30 AMApple acquires AI startup specializing in overlooking manufacturing componentsau.lifestyle.yahoo.com - March 15 at 1:30 AMInfectious disease outbreak at major festivalmsn.com - March 15 at 1:30 AMTwo words health boss wants scrappedau.news.yahoo.com - March 14 at 8:29 PMSeven tips on how to lower your blood pressure, according to Doctor Hilary Jonesau.news.yahoo.com - March 14 at 3:28 PMShort Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Decreases By 46.8%marketbeat.com - March 14 at 2:22 PMBioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 14 at 10:28 AMAs Hershey battles cocoa costs, chocolate lovers may help cool inflationmsn.com - March 14 at 5:27 AMCovid patients wrongly issued with ‘do not resuscitate’ orders, watchdog findsmsn.com - March 14 at 5:27 AMBuy Rating Affirmed for BioXcel Therapeutics Amid Label Expansion and Strong Clinical Prospectsmarkets.businessinsider.com - March 14 at 5:27 AMQ4 2023 BioXcel Therapeutics Inc Earnings Callfinance.yahoo.com - March 13 at 2:15 AMHere's what Wall Street expects from BioXcel Therapeutics's earningsmarkets.businessinsider.com - March 12 at 4:14 PM Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address AI “wealth window” is closing June 25th (Ad)Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry. I put together this personal video [HERE]… BTAI Media Mentions By Week BTAI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BTAI News Sentiment▼0.000.36▲Average Medical News Sentiment BTAI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BTAI Articles This Week▼25▲BTAI Articles Average Week Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Allakos News Oramed Pharmaceuticals News PMV Pharmaceuticals News OptiNose News Clearside Biomedical News Cue Biopharma News Anixa Biosciences News IO Biotech News Eton Pharmaceuticals News DiaMedica Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BTAI) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders“Crash Insurance” For Your RetirementUnstoppable ProsperityThe #1 Crypto for AIWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
